KDM6A is altered in 7.41% of medulloblastoma patients [3].

KDM6A is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [4].

KDM6A is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

KDM6A is altered in 30.62% of bladder carcinoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

KDM6A is altered in 6.25% of desmoplastic/nodular medulloblastoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is altered in 6.25% of large cell/anaplastic medulloblastoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is altered in 3.73% of malignant solid tumor patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) [4].

KDM6A is altered in 5.17% of central nervous system embryonal neoplasm patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is altered in 2.15% of glioblastoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain KDM6A status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

KDM6A is altered in 2.35% of breast carcinoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KDM6A status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

KDM6A is altered in 1.12% of anaplastic astrocytoma patients [3].

KDM6A is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain KDM6A status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

KDM6A is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain KDM6A status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KDM6A is altered in 6.74% of endometrial endometrioid adenocarcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 4.97% of anaplastic oligodendroglioma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is altered in 4.03% of sarcomatoid carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 3.21% of melanoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 5.08% of head and neck carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 4.91% of malignant ovarian endometrioid tumor patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 2.92% of colorectal carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 2.17% of high-grade glioma, NOS patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is altered in 2.61% of non-small cell lung carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 2.13% of malignant glioma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is altered in 2.13% of diffuse glioma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is altered in 4.07% of pancreatic carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 1.75% of anaplastic ependymoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is altered in 3.36% of ovarian carcinoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 2.86% of malignant ovarian clear cell tumor patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 2.0% of lymphoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 0.84% of synovial sarcoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 1.57% of sarcoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is altered in 1.11% of soft tissue sarcoma patients [3].

KDM6A is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

KDM6A is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].